Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danuglipron Phase 1 Dose-Escalation in T2DM
NCT03538743Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jun 2018
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of danuglipron in type 2 diabetes mellitus (T2DM) (9 arms), sponsored by Pfizer. Primary endpoints: Number of Participants With All-causality and Treatment-related Treatment-emergent Adverse Events (TEAEs) up to 63 days, Number of Participants With Laboratory Abnormalities Without Regard to Baseline Abnormality up to 42 days and 2 more. Started Jun 2018; status: completed.
02
Drugs
danuglipron
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03538743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03538743.